Two Sigma Securities’s Brainstorm Cell Therapeutics BCLI Stock Holding History
Bought
Maintained
Sold
Other funds holding BCLI
Two Sigma Securities's BCLI Position: Q2 2025 in Review
Two Sigma Securities sold out of Brainstorm Cell Therapeutics (BCLI) in Q2 2025, closing a stake of 16,153 shares — an estimated $20.4K sold.
Two Sigma Securities first reported a position in BCLI in Q3 2023 and held it in 5 quarters. The position peaked at $34.5K in Q2 2024. 34 funds tracked by Wall St. Rank hold BCLI as of Q2 2025.
- Two Sigma Securities reported no remaining Brainstorm Cell Therapeutics position as of Q2 2025 after selling out during the quarter.
- Two Sigma Securities sold 16,153 Brainstorm Cell Therapeutics shares in Q2 2025, an estimated $20.4K.
- Two Sigma Securities first reported a position in Brainstorm Cell Therapeutics in Q3 2023 and held it in 5 quarters.
- Two Sigma Securities's Brainstorm Cell Therapeutics position peaked at $34.5K in Q2 2024.
- 34 funds tracked by Wall St. Rank held Brainstorm Cell Therapeutics as of Q2 2025.
Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.